# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-23-023073
Filing Date
2023-05-05
Accepted
2023-05-05 07:00:14
Documents
6
Period of Report
2023-06-16

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20008400x2_def14a.htm | DEF 14A | 961975
2 |  | ny20008400x2_pc01.jpg | GRAPHIC | 556073
3 |  | ny20008400x2_pc02.jpg | GRAPHIC | 324270
4 |  | ny20008400x2_pvp01.jpg | GRAPHIC | 128030
5 |  | ny20008400x2_pvp02.jpg | GRAPHIC | 129394
6 |  | ny20008400x2_pvp03.jpg | GRAPHIC | 114274
| Complete submission text file | 0001140361-23-023073.txt |  | 2686441

Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-11460 | Film No.: 23891166
SIC: 2834 Pharmaceutical Preparations